Company Overview and News

 
Montezuma Mining shareholders confirm name change to Element 25

2018-05-14 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has received shareholder approval to change the company’s name and ticker to Element 25 Ltd (ASX:E25).

 
Montezuma Mining scoping study results support manganese mining operation

2018-05-10 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has received scoping study results for its 100% owned Butcherbird Manganese Project in Western Australia.

 
Montezuma Mining Company in trading halt ahead of scoping study release

2018-05-08 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has been granted a trading halt by the ASX pending the release of the Butcherbird Manganese Project scoping study.

 
Montezuma Mining to rename company Element 25

2018-04-09 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) is a diversified explorer focused on manganese, cobalt, lithium and gold.

 
Montezuma Mining prepares to reveal manganese scoping study results

2018-04-09 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) is on schedule to release scoping study results this month for its Butcherbird Manganese Project located in Western Australia.

 
Montezuma Mining does deal with Magmatic Resources for Mt Venn

2018-03-14 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has entered a binding agreement with Magmatic Resources Ltd (ASX:MAG) to sell an exploration tenement at the Mt Venn intrusion, Western Australia.

 
Montezuma Mining Company expedites manganese project with mining lease application

2018-02-28 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) recently initiated a scoping study to review the potential for the Butcherbird Manganese Project located in Western Australia.

 
Montezuma Mining engages consultants for manganese commercial studies

2018-02-11 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has appointed two consulting groups to carry out key sections of commercial studies for the Butcherbird Manganese Project in Western Australia.

 
Montezuma Mining Company assesses options to produce high purity manganese

2018-01-16 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has started a scoping study to assess production of high purity manganese from the Butcherbird Project in Western Australia.

 
Montezuma Mining Company results show high-purity, battery-grade manganese

2017-11-21 proactiveinvestors.com.au
Montezuma Mining Company Ltd (ASX:MZM) has received more results from test work on the design of a hydrometallurgical flowsheet for its 100% owned Butcherbird Manganese Project in Western Australia.

 
Alt Resources drills gold at multiple prospects

2017-11-06 proactiveinvestors.com.au
Alt Resources (ASX:ARS) has completed a 1,490-metre greenfields reverse circulation drilling program at the Mt Roberts Gold Project near Leinster in Western Australia.

 
Montezuma Mining Company shares continue to rise

2017-10-31 proactiveinvestors.com.au
Montezuma Mining Company (ASX:MZM) shares have doubled over the past three months, currently priced at $0.27.

 
Montezuma’s Munich report highlights EV manganese push

2017-10-30 australianmining.com.au
Montezuma Mining has released a report from its recent Munich conference highlighting what it calls a ‘tech metal supercycle’, the material supply of manganese for electric vehicles (EVs).

 
Montezuma Mining Company reveals high-grade gold anomaly

2017-10-18 proactiveinvestors.com.au
Montezuma Mining Company (ASX:MZM) has successfully completed an induced polarisation (IP) survey at its 100% owned Holleton Gold Project in southwest Western Australia.

 
Montezuma upgrades WA manganese mine

2017-10-12 australianmining.com.au
Montezuma Mining has upgraded its 100 per cent-owned Yanneri Ridge manganese facility in Butcherbird, Western Australia — the largest onshore facility of its type in the country — following optimistic test results that have exceeded expectations.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...